Embed
Email

HIV & AIDS

Document Sample
HIV & AIDS
Shared by: HC11113019828
Categories
Tags
Stats
views:
0
posted:
11/30/2011
language:
English
pages:
146
HIV & AIDS



Lecturer: Dr. A. van Graan

Acknowledgements: Hilary Woodley

HIV & AIDS

 Human immunodeficiency virus (HIV)

 Acquired immunodeficiency syndrome

(AIDS)

 Primary infection with HIV is the

underlying cause of AIDS

Incidence & Prevalence









WHO Report

Incidence & Prevalence









UN GLOBAL SUMMARY OF THE AIDS EPIDEMIC update: DECEMBER 2005

Incidence & Prevalence



Total:

40.3 million

(36.7-45.3)









UNAIDS/WHO

Incidence & Prevalence



Total:

4.9 million

(4.3-6.6)









UNAIDS/WHO

Incidence & Prevalence



Total:

3.1 million

(2.8-3.6)









UNAIDS/WHO

Incidence & Prevalence









UN GLOBAL SUMMARY OF THE AIDS EPIDEMIC update: DECEMBER 2005

Incidence & Prevalence

 Sub-Saharan Africa has just over 10% of the

world’s population

 more than 60% of all people living with HIV

 2005, an estimated 3.2 million in the region

became newly infected

 2.4 million adults and children died of AIDS

 young people aged 15–24 years 4.6% of women

and 1.7% of men were living with HIV in 2005



WHO Report

Incidence & Prevalence

Incidence & Prevalence









UN GLOBAL SUMMARY OF THE AIDS EPIDEMIC update: DECEMBER 2005

Incidence & Prevalence

 HIV prevalence among pregnant women:

 highest levels to date: 29.5% (DOH in 2004)

 women aged 25–34 years - more than 1 in 3

estimated HIV+

 women aged 20–24 years - almost 1 in 3 was

infected

 KwaZulu-Natal 40%

 Eastern Cape, Free State, Gauteng, Mpumalanga

and North West provinces 27% - 31%

 late teens (15–19 years) 15 - 16% since 2000

 20–24 year-old 28% - 31% in 2000–2004

(Department of Health, 2005)

Incidence & Prevalence









UN GLOBAL SUMMARY OF THE AIDS EPIDEMIC update: DECEMBER 2005

Incidence & Prevalence

 death registration data has shown that

deaths among people:

 15 years of age and older increased by 62%

in 1997–2002

 25–44 years more than doubling

 nearly 2.9 million death notification

certificates more than 1/3 of all deaths were

among people in that age group

(Statistics SA, 2005)

HIV & AIDS

 HIV invades the genetic core of the CD4+

or T-helper lymphocyte cells, the principal

agents involved in protection against

infection

HIV & AIDS

 CD4+ cell count in blood is the common

laboratory test used

 other distinct compartments contain virus

and evolve separately:

 semen

 vaginal secretions

 the lymph system and

 the central nervous system

HIV & AIDS

 HIV infection causes a progressive

depletion of CD4+ cells, which eventually

leads to:

 immunodeficiency

 constitutional disease

 neurologic complications

 opportunistic infections and

 neoplasms

HIV & AIDS

 HIV can be transmitted via:

 blood

 semen

 presemenal fluid

 vaginal fluid

 breast milk and

 other body fluids that contain blood

HIV & AIDS

 HIV can be transmitted via:

 cerebrospinal fluid surrounding the brain and

spinal cord

 synovial fluid surrounding bone joints and

amniotic fluid surrounding a foetus are other

fluids that can transmit HIV

HIV & AIDS

 HIV can NOT be transmitted via:

 saliva

 tears and

 urine

 contact-touching

 hugging or kissing

 through using the same plates, silverware or

drinking glasses

HIV & AIDS

 most common way HIV is transmitted is

via:

 blood and semen during unprotected anal or

vaginal intercourse with an HIV-infected

person

 risk of transmission through oral sex is

considered low but not risk-free

HIV & AIDS

 Transmission can also occur by:

 sharing of contaminated needles

 injection of contaminated blood products

 by transfer from an infected mother to her

baby before or during birth

 through breast-feeding

HIV & AIDS

 All persons should use universal

precautions to protect both themselves

and others when working with body fluids

HIV & AIDS

 Two types of HIV:

 HIV-1: Majority of HIV infection worldwide

 HIV-2: West Africa



 HIV-l mutates readily and has different

strains, which have many subtypes and

groups and are found distributed unevenly

throughout the world

HIV & AIDS

 HIV-1 strains

• Group M (major) – prevalent – 90% of cases

• Group O (outlier) – rare and quite diverse

• Group N (new) – recently described in Cameroon

 HIV-1 subtypes (clades) – A to J

• Initial epidemic in South Africa: B  C

 The reason for the genetic diversity is related

to inherent potential of virus to mutate

Manifestations & stages

 After exposure and transmission of HIV

into the host

 HIV spreads throughout the body and

blood CD4+ cell counts fall dramatically

Manifestations & stages

 An immune response follows

 CD4+ cells can return to almost normal

and

 virus in the blood falls to an undetectable

level

Manifestations & stages

 During this period of clinical latency

 CD4+ cells de-crease to below a level at

which increased risks of opportunistic

infections occur

 Untreated, HIV eventually replicates at

800 billion virus particles per day

Manifestations & stages

 Both the World Health Organization and

the Centre’s for Disease Control have set

criteria for defining AIDS

 The WHO staging is clinical and useful in

resource poor areas where laboratory

facilities are not always available

Manifestations & stages

WHO CDC

 Clinical system  Clinical + Lab

 Stage 1 - 4  Stage A – C + 1 – 3

 Includes functional  Does not include

status functional status

Manifestations & stages

Krause 11th ED

 Four stages of the disease have been

characterized:

(1) acute HIV infection

(2) asymptomatic chronic HIV infection

(3) symptomatic HIV infection

(4) AIDS or advanced HIV

Lymphadenopathy

www.aids-hiv.cz/ diagnostika.htm

Manifestations & stages

Krause 11th ED

 Acute human immunodeficiency virus

(HIV) infection:

 4- to 7 -week period immediately after

infection

 viral replication is rapid

Manifestations & stages

Krause 11th ED

Acute human immunodeficiency virus (HIV) infection:

 30 - 60% of newly infected persons develop an acute

syndrome with:

 Fever

 Malaise

 Lymphadenopathy syndrome (LAS)

 Pharyngitis

 Headache

 Myalgia and sometimes rash

which may last for a week to a month

Manifestations & stages

Krause 11th ED

Acute human immunodeficiency virus (HIV) infection:

 The time period between the initial HIV infection and

seroconversion (the development of HIV antibodies)

varies from 1 week to several months or more

 Once antibodies to HIV appear in the blood, individuals

with and without symptoms will test positive for HIV

 Viral load is extremely high, and individuals are very

infectious at this time.

Manifestations & stages

Krause 11th ED

Asymptomatic HIV stage:

 few, if any, noticeable symptoms occur

 last from a few months to as long as 10 years

 Subclinical changes have been reported:

 decrease in lean body mass without apparent total

body weight change

 vitamin B12 deficiency and

 increased susceptibility to food borne and

waterborne pathogens

Manifestations & stages

Krause 11th ED

Symptomatic HIV occurs when symptoms appear

(CDC Category B)

 symptoms may include:

 fevers

 sweats

 skin problems

 fatigue or

 other symptoms that are not AIDS-defining

 a decline in nutrient status or body composition

may also occur

Manifestations & stages

Krause 11th ED

AIDS, or advanced HIV disease:

 the diagnostic term reserved for those

persons with at least one well-defined,

life-threatening clinical condition that is

clearly linked to HIV-induced

immunosuppression (CDC Category C)

Manifestations

& stages



CD4 cell

counts and

associated

conditions



Krause 11th Ed,

Table 41.1

Manifestations

& stages



CD4 cell

counts and

associated

conditions



Krause 11th Ed,

Table 41.1

Manifestations

& stages



Categories for

Children



Krause 11th Ed,

Table 41.2

CDC 1993 Clinical categories

A B C

CD4+ cell Asympt. Symptomatic

(not A or C) Aids indicator

count or diseases

categories

PGL





1

> 500/mm3 A1 B1 C1



2

200–499/mm3 A2 B2 C2



3

< 200/mm3 A3 B3 C3

Manifestations

& stages



CDC 1993



Krause 11th Ed,

Box 41.1

Opportunistic Infections and Other

Complications

 Opportunistic infections with:

 bacteria

 fungi

 protozoa or

 viruses



are common in this population

Opportunistic Infections and Other

Complications

 They are often cause:

 diarrhoea

 malabsorption

 fever and

 weight loss



as well as many other symptoms

Opportunistic Infections and Other

Complications

Malignant Disease

 Kaposi's sarcoma (KS) is a malignant disease of

the peripheral blood mononuclear cells that

manifests as purple nodules on the:

 skin

 mucous membranes

 lymph nodes

 gastrointestinal tract







www.thachers.org/ images/Kaposi2.jpg

Opportunistic Infections and Other

Complications

Malignant Disease

 KS lesions in the oral cavity or

oesophagus may cause:

 pain and difficulty with chewing and

swallowing

 KS lesions in the intestinal tract have been

implicated in:

 diarrhoea and intestinal obstruction

Opportunistic Infections and Other

Complications

Malignant Disease

 Lymphomas include:

 non-Hodgkin's lymphoma and Burkitt's

lymphoma that involve the small bowel

can cause:

 malabsorption

 diarrhoea

 intestinal obstruction

Opportunistic Infections and Other

Complications

Malignant Disease

 Lymphomas include:

 Primary lymphoma in the brain can cause

alterations in:

 personality

 motor and cognitive abilities

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Immediately following infection, HIV enters

the brain and may result in:

 HIV encephalopathy (AIDS dementia)

 myelopathy

 peripheral neuropathy and

 myopathy

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Secondary neurologic complications may result

from:

 toxoplasma encephalitis

 progressive multifocal leukoencephalopathy

 cytomegalovirus (CMV) encephalitis

 radiculomyelitis

 cryptococcal eningitis

 primary central nervous system lymthoma

 neurosyphilis

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Before there were medications to control

viral replication, dementia affected 25% of

those living with HIV

 today the rate of HIV-associated dementia

is below 10%

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Symptoms of AIDS dementia may include

deterioration in:

 cognition (concentration, recall, new memory

development, language)

 motor function (coordination, gait, bladder control)

 behaviour (psychosis, depression, withdrawal)

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Viral load in the brain and the level of

neurologic decline are not strongly

correlated

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Myelopathy (disease of the spinal cord) may

occur in as many as 25% of those with

advanced HIV disease and can result in partial

paralysis of the lower extremities (paraparesis)

 Myelopathy affects motor and sensory functions

and is manifested by:

 spasticity

 weakness in the legs and

 bladder

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Myopathy – (progressive muscle weakness) is

usually a result of:

 HIV infection or

 toxicity from AZT (If AZT is the underlying

cause, creatine kinase levels are usually

elevated)

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Approximately 20% of patients with AIDS

experience peripheral neuropathy, which is

characterized by:

 sensory loss

 pain

 weakness

 wasting of muscle in the hands or legs and feet

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 The first signs of peripheral neuropathy

are:

 tingling

 burning

 numbness



in the toes and fingers

Opportunistic Infections and Other

Complications

Neuromuscular Diseases

 Peripheral neuropathy may be caused by:

 the virus or

 drugs (zalcitabine, didanosine, and

stavudine)

Opportunistic Infections and Other

Complications

HIV-Liver Disease

 Hepatitis C (HVC) is now considered an

HIV opportunistic infection

 Those with both HIV and HVC have a

faster progression to AIDS and death

 current HVC treatments do not seem to

alter outcome in HIV-infected persons

Opportunistic Infections and Other

Complications

HIV-Liver Disease

 Liver function may be compromised by:

 the use of highly active antiretroviral therapy

 infection with cytomegalovirus (CMV)

 cryptosporidia

 hepatitis B

 by hepatic malignant diseases, such as KS or

lymphoma

Opportunistic Infections and Other

Complications

Tuberculosis and Lung Diseases

 most cases of tuberculosis (TB) affect the lungs

 in HIV-infected persons may also occur in

extrapulmonary sites such as the:

 larynx

 lymph nodes

 brain

 kidneys

 bones

Opportunistic Infections and Other

Complications

Tuberculosis and Lung Diseases

 Medical conditions that increase the risk of TB

infection include:

 HIV infection

 a body weight that is 10% or more below ideal weight

 immunosuppressive therapy

 hematologic disorders such as leukemia and

lymphomas

Opportunistic Infections and Other

Complications

HIV-Associated Nephropathy

 HIV associated nephropathy (HIVAN), a syndrome of

progressive renal failure may occur

 Proteinuria may also result from:

 repeated infections

 volume depletion

 nephrotoxic drugs

 Acute renal failure

 Deaths from kidney disease have increased

 Dosing of drugs and nutrition therapy must be adjusted

for those with renal failure

Opportunistic Infections and Other

Complications

Other Affected Organ Systems

 Chronic diarrhoea in the absence of identifiable

enteric pathogens due to AIDS enteropathy

 HIV enteropathy may have villous atrophy and

abnormal results on tests of small bowel function

 Because of the vulnerability of persons with

immune suppression to foodborne and

waterborne pathogens, food and water safety is

a concern

Opportunistic Infections and Other

Complications

Other Affected Organ Systems

 Intestinal injury is related to specific

complications rather than to the

immunodeficiency

Food safety …

HIV / AIDS:

 Campylobacter

 (AIDS 35x more frequently)

 Listeria and

 (AIDS 100x more frequently)

 Salmonella

 (AIDS more common see egg guidelines)

Egg cooking guidelines

 yolk and white are firm, not runny

 Scrambled -1 minute at medium stove top setting (250

deg F for electric frying pans)

 Sunnyside -7 minutes at medium setting (250 deg F) or

cook covered 4 minutes at 250 deg F

 Fried, over easy -3 minutes at medium setting (250 deg

F) on one side, then turn and fry for another minute on

the other side

 Poached -5 minutes in boiling water

 Boiled -7 minutes in boiling water

http://vm.cfsan.fda.gov/~dms/aidseat.html

Medical management

Highly active antiretroviral therapy (HAART)

 a combination of at least 3 anti-retroviral

agents (ART) used to suppress:

 viral replication

 progression of HIV disease







ART DOES NOT ERADICATE HIV

Medical management

Highly active antiretroviral therapy (HAART)

3 drug classes include:

 NRTIs = Nucleoside reverse transcriptase

inhibitors

 NNRTIs = Non-nucleoside reverse

transcriptase inhibitors

 PIs = Protease inhibitors

Medical management







NRTIs – inhibit virus replication by directly

blocking chain extention during reverse

transcription using nucleoside analogues as

chain terminators

NNRTIs - inhibit virus replication by binding

directly to the reverse transcriptase and

preventing reverse transcription

Medical management





NRTIs

NNRTIs

PIs inhibit formation of

mature infectious virus

particles by blocking

protease activity and

thereby preventing

cleavage of the gag-pol

polyprotein

Medical management

Highly active antiretroviral therapy (HAART)

 use of only one antiretroviral drug has

been recognized as leading to drug

resistant mutants of the virus

Medical management

HAART Therapy considers:

1. Viral Load Levels (HIV-RNA) which predict the risk of

HIV disease progression, and when to initiate or change

therapy

2. Current and lowest CD4+ counts for the extent of HIV-

induced immune damage and the risk for opportunistic

infections

3. Current and past clinical conditions and symptoms of

HIV disease, including history of treatment outcomes

4. Life stage: children, adolescents and pregnant women

warrant special considerations

Medical management

Concerns about HAART that need to be

considered in developing nutritional

plans include the following:

 Viral resistance can occur

Medical management

Concerns about HAART that need to be

considered in developing nutritional plans

include the following:

 Patients must adhere to daily-and often

very complicated-drug schedules, which

may have bothersome meal and food

requirements

(NB see Krause 11th ED Table 41-5)

Medical management

Concerns about HAART …

 One must be more than 95% adherent for

medications to work correctly. Late, missed, or

non-meal-coordinated medications increase

risks for:

 suboptimal dosing

 viral breakthrough

 the development of drug-resistant strains of HIV

Medical management

Concerns about HAART that need to be

considered in developing nutritional

plans include the following:

 Not all patients tolerate antiretroviral

drugs.

Medical management

Concerns about HAART that need to be

considered in developing nutritional plans

include the following:

 New adverse complications have emerged:

 body fat accumulation and fat atrophy

 Hyperlipidemia

 insulin resistance or glucose intolerance

 osteopenia and osteoporosis

 avascular necrosis

 bone fracture

 lactic acidosis

 mitochondrial toxicity

Regional fat accumulation









Aboulafia and Bundow 1998 Carr and Cooper 1998 aidsmyth.addr.com

Facial waisting









www.emedicine.com/derm/topic877.htm

Medical management

Concerns about HAART that need to be

considered in developing nutritional plans

include the following:

 The loosely termed lipodystrophy syndrome

stems from one or more of the following causes:

 drug side effects

 extended exposure to the virus or activated immune

cells characteristic of HIV infection

 immune system alterations along with suppression of

the virus by the drugs

Medical management

Concerns about HAART that need to be

considered in developing nutritional plans

include the following:

 Medication costs

Medical management

Medical management

 NB see Krause 11th ED Table 41-5

Medical management

Ingestion

 Both drugs and disease can cause

changes in:

 appetite and

 nutrient intake



 resultant malnutrition can affect drug

efficacy

Medical management

Absorption

 Drugs and foods can have mechanical effect, via

binding or adsorption that can influence the

absorptive processes resulting in ↑ or ↓ drug and

nutrient absorption.

 Some drugs can affect gastrointestinal motility

thereby ↑ or ↓ absorption of nutrients.

 Chemical factors, in particular pH of the stomach

contents and the influence of foods therein, can

affect the subsequent absorption of drugs.

Medical management

Transluminal transport

 The ability of drugs and nutrients to be

transported can depend on such factors

as:

 lipid solubility and

 competition for amino acid transport

systems

Medical management

Metabolism

 The effectiveness of the mixed function

oxidase (MFO) and conjugase systems in

the liver and elsewhere for converting

drugs and nutrients into their active and,

ultimately, excretory forms depends on the

availability of specific nutrient cofactors.

Medical management

Metabolism

 In addition, certain drugs can increase the

activity of the MFO systems required to

convert nutrient precursors into their active

forms. Nonnutritive components in foods

can induce MFO activity, thereby affecting

drug metabolism.

Medical management

Distribution

 The utilization of both drugs and nutrients

depends on body composition, the

availability and functional integrity of

transport proteins, receptor integrity and

intracellular metabolic machinery

Medical management

Elimination

 Drugs and nutrients can synergistically

and competitively interact to cause

increased or decreased excretion.

 Systemic factors such pH and

physiological state (e.g., sweating) can

dictate whether a drug or nutrient is

excreted or resorbed.

In conclusion on ART

 An intimate link exists between pharmacology

and nutrition that is affected by stage of

development and physiological differences (i.e.,

gender, physiological state)

 In areas were malnutrition and HIV infection

coexist, it will be essential to incorporate a full

appreciation of the important role of diet and

nutrition in the implementation of those

strategies designed to prevent and treat

HIV/AIDS in adults, infants and children

In conclusion on ART

 Documentation is needed of dietary

supplement use including use of herbal

and botanical therapies (that can

potentially cause drug/supplement

interactions which in turn affect the

efficacy, safety and/or compliance with

ART)

Malnutrition and HIV & AIDS

 complex interactions between nutrition and

HIV/AIDS

 HIV progressively weakens the immune

system and

 malnutrition itself may also increase the

susceptibility to infections

Malnutrition and HIV & AIDS









Oxford Handbook of HIV medicine

Malnutrition and HIV & AIDS

HIV infection co-exists with:

 macronutrient malnutrition - protein-energy

malnutrition (PEM) and

 hidden hunger of micronutrient

deficiencies

Nutrient requirements

 Weight loss in adults and growth failure in

children are common in HIV/AIDS infected

children and adults









www.usnews.com/usnews/

photography/aids/aids1.htm

Nutrient requirements

Energy

 requirements are likely to increase by 10% to

maintain body weight and physical activity in

asymptomatic HIV-infected adults

 An additional 20–30% increase in energy needs

occurs during the convalescent catch-up period

after a severe infection

 During symptomatic HIV, and subsequently

during AIDS, energy requirements increase by

approximately 20% to 30% to maintain adult

body weight

WHO 2004

Nutrient requirements

Energy

 These targets should be achieved through

food-based approaches whenever

possible

 Pregnant and lactating requirements the

same as non HIV infected women

Nutrient requirements

Energy

 Normal energy requirements:

 30-35 kCal/kg/day

 Malnourished:

 40-45 kCal/kg/day





Nicus fact sheet, 2002

Nutrient requirements

Protein

 Loss of body protein during HIV/AIDS is

therefore caused by:

 poor diet

 malabsorption

 endogenous intestinal losses and

 altered metabolism



all are more striking during opportunistic infection

Nutrient requirements

Protein

 no evidence for increased protein

requirement over and above that required

in a balanced diet to satisfy the total

energy requirements

 12 to 15% of the total energy intake

Nutrient requirements

Fat

 no evidence that fat requirements are

different because of HIV infection

Nutrient requirements

Micronutrients

 To ensure micronutrient intakes at RDA

levels, HIV-infected adults and children

are encouraged to consume healthy diets

Nutrient requirements

Micronutrients

 A synergistic relationship exists when a

specific micronutrient deficiency increases

infectious disease morbidity

 in which case either improved

micronutrient intake or treatment of the

infection will break the vicious circle

Nutrient requirements

Micronutrients

 But an antagonistic relationship can also

exist when a specific micronutrient

deficiency reduces - or increased intake

increases - infectious disease morbidity

Nutrient requirements

Micronutrients

 Then some micronutrients may act

synergistically in moderate doses but

antagonistically in high doses

 Example, zinc, although essential to the

immune system is immunosuppressive in

high doses

Nutrient requirements

Micronutrients

 dietary intake of micronutrients at RDA

levels may not be sufficient to correct

nutritional deficiencies in HIV-infected

individuals

Nutrient requirements

Micronutrients

 BUT there is evidence that some

micronutrient supplements, e.g. vitamin A,

zinc and iron, can produce adverse

outcomes in HIV-infected populations

Nutrient requirements









WHO Micronutrients and HIV infection: a review of current evidence April 2005

Nutrient requirements









WHO Micronutrients and HIV infection: a review of current evidence April 2005

Nutrient requirements

Vitamin A

 the importance of vitamin A to immune

functions and childhood infections and

mortality, it is plausible that vitamin A is

beneficial in HIV infection

 However, in vitro studies in different cell

lines suggest that vitamin A may both

reduce and increase viral replication

Nutrient requirements

Vitamins B, C and E

 Several of the B vitamins as well as

vitamins C and E have been associated

with reduced risk of HIV progression in

observational studies

Nutrient requirements

Iron

 Iron deserves special mention because

both the effect of HIV infection on status

and the effect of status and intake on HIV

infection seem to be different from those of

other micronutrients

Nutrient requirements

Iron

 Iron may have adverse effects in HIV and

other viral infections data suggest that iron

may increase the susceptibility to and

severity from common and opportunistic

infections, such as tuberculosis

Nutrient requirements

Iron

 Iron may have adverse effects in HIV and

other viral infections data suggest that iron

may increase the susceptibility to and

severity from common and opportunistic

infections, such as tuberculosis

Nutrient requirements

Zinc

 Zinc is a component of both structural and

catalytic proteins of HIV

 Zinc is required for the activity of reverse

transcriptase and the production of

infectious virus and may inhibit HIV

replication through binding to the catalytic

site of HIV protease

Nutrient requirements

Zinc

 The association between zinc intake and

increased progression to AIDS and death, found

in one cohort study in U.S. patients with a high

intake of highly bioavailable zinc but not in

another, may have delayed assessment of the

effect of zinc supplementation in populations at

risk of zinc deficiency

Nutrient requirements

Zinc

 Given the considerable importance of zinc for

immune functions and in the prevention of

diarrhoea and respiratory tract infections, it is

likely to play a role in HIV infection

 A RCTs in adults with pulmonary TB co-infected

with HIV found no significant effect of 45 mg of

zinc daily during TB treatment on viral load

 In fact, zinc in combination with other

micronutrients considerably increased weight

gain and seemed to increase survival during

treatment

Nutrient requirements

Selenium

 despite the finding from several

observational studies that low serum

selenium is strongly associated with HIV

progression, there are no reports of the

effect of selenium supplementation on viral

load or clinical HIV endpoints although

reduced hospitalization rate was reported

Nutrient requirements

Micronutrients and Pregnancy

 To prevent anaemia, WHO recommends daily

iron-folate supplementation (400 μg of folate and

60 mg of iron) during six months of pregnancy,

and to treat severe anaemia twice-daily

supplements

 Available data do not support a change in this

recommendation for women living with HIV

Nutrient requirements

Micronutrients and Pregnancy

 Daily vitamin A intake by HIV-infected women during

pregnancy and lactation should not exceed the RDA

 In areas of endemic vitamin A deficiency, WHO

recommends that a single high-dose of vitamin A (200

000 IU) be given to women as soon as possible after

delivery, but no later than six weeks after delivery

 Research is under way to assess further the effect of

singledose, postpartum vitamin A supplementation

among HIV-infected women

Nutrient requirements

In conclusion

 Use of a multivitamin supplement not

exceeding more than 2x the RDA (200%)

Nutrient requirements

Fluid requirements

 Same as for healthy individuals

 30-35ml/kg/day

 Compensate for:

 Diarrhea (electrolyte replacement NB)

 Nausea

 Vomiting (electrolyte replacement NB)

 Night sweats

 Prolonged fever

Nutrient requirements

NB Practical eating suggestions for

symptom management

 Box 41.4 Krause 11th Ed pg 1050

 South African National Guidelines on

Nutrition for People living with TB,

HIV/AIDS and other chronic debilitating

conditions www.sun.ac.za/nicus

 What to do if … notes

Nutrient requirements

NB Nutrition intervention for diarrhea

 Table 41.7 Krause 11th Ed pg 1052





NB Food safety

 South African National Guidelines on

Nutrition for People living with TB,

HIV/AIDS and other chronic debilitating

conditions www.sun.ac.za/nicus

HIV & AIDS

Websites used for complilation of slides:

 www.unaids.org

 www.sun.ac.za/nicus

 www.who.int

HIV & AIDS

For further information on the following South African

Department of Health articles

 HIV/AIDS related

 Guidelines for the management of HIV-infected children - 2005

 Monitoring and Evaluation of the Operational Plan for

Comprehensive HIV and AIDS Care, management and Treatment

for South Africa

 - Training Manual for Facilitators - April 2005

 - Training Manual for Participants - April 2005

 National Antiretroviral Treatment Guidelines - 2004

 Circular Minute on Prevention of Mother-To-Child Transmission of

HIV - 16 April 2002

Visit http://www.doh.gov.za/docs/facts-f.html

Oral Candidiasis









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA

Oral Candidiasis









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA

Oesophageal Candidiasis









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA

Oral Hairy

Leukoplakia









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA

Clinical picture – Oral KS









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA

Disseminated herpes









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA

Herpes Zoster









Dr Emille Reid, Senior Specialist Physician: Internal Medicine & Infectious Diseases, UKWANDA


Related docs
Other docs by HC11113019828
Arkansas Department of Education
Views: 0  |  Downloads: 0
????? ???????? ??????? - 13
Views: 1  |  Downloads: 0
?�???????????????????? ...
Views: 0  |  Downloads: 0
Akkari IIPE PRESENTATION
Views: 2  |  Downloads: 0
Robinson Jeffrey FINAL 09 12 08
Views: 6  |  Downloads: 0
OCF Reg Crew Phone List 2009
Views: 10  |  Downloads: 0
Meysen 06 11 2009
Views: 0  |  Downloads: 0
July 2009
Views: 0  |  Downloads: 0
By registering with docstoc.com you agree to our
privacy policy

You are almost ready to download!

You are almost ready to download!